E-cadherin and c-Met expression in actinic cheilits and lip squamous cell carcinoma

Riparsaponin isolated from Homonoia riparia Lour induces apoptosis of oral cancer cells

Homonoia riparia Lour (Euphorbiaceae) is a known source of herbal medicine in China, and riparsaponin (RSP) is an active constituent isolated from H. riparia. The aim of the present study was to investigate the antitumor effect of RSP on human oral carcinoma cells and its potential underlying molecular mechanism. RSP was isolated from roots of H. riparia and identified using nuclear magnetic resonance. An MTT assay was used to evaluate the cytotoxicity of RSP on human oral carcinoma cells. Subsequently, DAPI staining was performed to investigate the apoptotic effect of RSP. To investigate the potential underlying molecular mechanism of action of RSP, western blotting was performed to determine the expression of cleaved caspase 3/9, B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), Bcl-2-associated death promoter (Bad), epithelial cadherin (E-CAD), c-MET, matrix metalloproteinase (MMP)-2 and MMP-9. RSP exhibited a significant anti-proliferative effect on oral carcinoma cells at concentrations between 10 and 200 µg/ml via apoptosis. Following treatment with RSP (20, 40 and 80 µg/ml), expression of cleaved caspase-3 (P<0.05, P<0.01 and P<0.01, respectively), cleaved caspase-9 (P<0.01), Bad (P<0.01), Bax (P<0.01), c-MET (P<0.01), MMP-2 (P<0.01) and MMP-9 (P<0.01) in oral carcinoma cells was increased significantly compared with the control group, whereas expression of Bcl-2 (P<0.01) and E-CAD (P<0.01) was decreased. These results suggest that RSP possessed notable antitumor activity against oral squamous cell carcinoma by inducing mitochondria-mediated apoptosis.

Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data

OBJECTIVES

The hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) ligand/receptor axis has been implicated in pathogenesis of malignant diseases including squamous cell carcinoma of the head and neck (SCCHN). Overexpression of c-MET has been reported as a common molecular abnormality in SCCHN, although its prognostic and predictive value remains to be validated.

METHODS

We systematically searched literature for studies evaluating c-MET expression on immunohistochemistry in newly diagnosed, non-metastatic SCCHN. The c-MET expressing cases were classified into three categories according to predefined cut-off values for positivity. Our aim was to assess the prevalence of c-MET expression and its relationship with selected clinicopathological variables.

RESULTS

Twenty-eight studies with 2019 cases were included. Relative frequencies of c-MET expression above cut-off levels I, II, and III were 81.8%, 63.8%, and 46.2%, respectively. Differences between these three values were statistically significant (p<1.0×10^-6). Above cut-off level II, c-MET positivity was associated with worse overall survival (p=4.0×10^-6), positive nodal status (p=1.0×10^-4), higher disease stage (p=7.0×10^-4), older age (p=2.1×10^-3), disease recurrence (p=2.0×10^-2), and primary tumour localization in the oral cavity (p=2.3×10^-2). Above cut-off level III, c-MET positivity was associated with worse disease-free or progression-free survival (p=9.0×10^-6), p16 negativity (p=2.4×10^-4), worse overall survival (p=4.0×10^-4), positive epidermal growth factor receptor (EGFR) status (p=7.2×10^-4), and larger primary tumours (p=4.6×10^-3).

CONCLUSION

In SCCHN, immunohistochemical overexpression of c-MET above cut-off levels III and particularly II was associated with inferior survival outcomes and advanced disease. Moreover, it represents a promising predictive biomarker for c-MET targeting, yet the optimal scoring method remains to be defined.